A phase Ib/II study evaluating Fruquintinib plus 5-Fluorouracil/Leucovorin (5FU/LV) beyond progression on Fruquintinib monotherapy in metastatic colorectal cancer

ABSTRACT: Interventions: experimental group:Fruquintinib plus 5-Fluorouracil /Leucovorin Primary outcome(s): recommended phase 2 dose (RP2D);6-month overall survival rate Study Design: Single arm

DISEASE(S): Metastatic Colorectal Cancer Beyond Progression On Fruquintinib Monotherapy

PROVIDER: 2693103 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR